For example, IL-12 locally produced significantly delayed peritoneal disease development in a mouse model [32], engineered tumor-targeted T cells ectopically expressing a fused IL12A/IL12B cDNA have been reported to eradicate ovarian tumors in vivo [31] and a highly significant association was found between high IFNG and IL12B expression and a more favorable clinical outcome of advanced stage ovarian carcinoma [30]. This evidence concerns the gene IL12A and ovarian carcinoma.